{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:15:13Z","timestamp":1761581713258,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.clgc.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T22:49:58Z","timestamp":1530139798000},"page":"473-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"16","author":[{"given":"Damian A.","family":"Laber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Jaglal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3995-4018","authenticated-orcid":false,"given":"Nathan","family":"Visweshwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.06.007_bib1","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1200\/JCO.2013.54.8404","article-title":"Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline","volume":"32","author":"Basch","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib2","first-page":"65","article-title":"Advances in the management of metastatic androgen-independent prostate cancer","volume":"104","author":"Laber","year":"2006","journal-title":"J\u00a0Ky Med Assoc"},{"key":"10.1016\/j.clgc.2018.06.007_bib3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.06.007_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.coc.0000221357.12412.b7","article-title":"A\u00a0phase II study of higher dose docetaxel in androgen-independent prostate cancer","volume":"29","author":"Laber","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib7","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.06.007_bib8","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1200\/JCO.2005.04.8207","article-title":"Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone","volume":"24","author":"Southwest Oncology","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2018.06.007_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.kjms.2013.07.004","article-title":"Oral etoposide and oral prednisone for the\u00a0treatment of castration resistant prostate cancer","volume":"30","author":"Zhu","year":"2014","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.clgc.2018.06.007_bib12","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1158\/1078-0432.CCR-08-3317","article-title":"Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer","volume":"15","author":"Fontana","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2018.06.007_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12032-016-0806-0","article-title":"Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial","volume":"33","author":"Calcagno","year":"2016","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00262-015-1781-6","article-title":"A\u00a0randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer","volume":"65","author":"Noguchi","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2018.06.007_bib15","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/cncr.28953","article-title":"Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients","volume":"120","author":"Derosa","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2018.06.007_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13577-012-0043-6","article-title":"Effects of etoposide on the proliferation of hexaploid H1 (ES) cells","volume":"25","author":"Fujikawa-Yamamoto","year":"2012","journal-title":"Hum Cell"},{"key":"10.1016\/j.clgc.2018.06.007_bib17","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.urology.2010.12.043","article-title":"Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032","volume":"77","author":"Smith","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2018.06.007_bib18","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1159\/000356580","article-title":"Estramustine-induced suicidal erythrocyte death","volume":"32","author":"Bissinger","year":"2013","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.clgc.2018.06.007_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib20","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.clgc.2015.08.008","article-title":"Effective and safe administration of low-dose estramustine phosphate for castration-resistant prostate cancer","volume":"14","author":"Inoue","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.06.007_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1442-2042.2009.02341.x","article-title":"Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer","volume":"16","author":"Matsumoto","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2018.06.007_bib22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/annonc\/mdn650","article-title":"Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer","volume":"20","author":"Spitaleri","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.06.007_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clgc.2018.06.007_bib26","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial\u2014FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clgc.2011.05.002","article-title":"Ten years of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and meta-analysis of 2244 patients in 12 randomized clinical trials","volume":"9","author":"Serpa Neto","year":"2011","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.06.007_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clgc.2014.04.008","article-title":"The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer","volume":"13","author":"Park","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.06.007_bib29","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/j.1464-410X.2011.10201.x","article-title":"The use of estramustine phosphate in the modern management of advanced prostate cancer","volume":"108","author":"Ravery","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2018.06.007_bib30","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1200\/JCO.2007.15.9830","article-title":"Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer","volume":"26","author":"Millikan","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.06.007_bib31","first-page":"CD006466","article-title":"Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation","author":"Akl","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318302921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318302921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:30:14Z","timestamp":1761564614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318302921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1558767318302921"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.06.007","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}